Meant Health Expands Telehealth for FDA-Approved GLP-1 Medications

MANASSAS, Va., Sept. 12, 2026 /CourierPR/ -- Meant Health, a digital health platform, has expanded its telehealth services to include FDA-approved GLP-1 medications, such as Ozempic. This move aims to bridge the gap between patients seeking treatment and licensed clinicians who can evaluate and prescribe medication based on individual health histories.

The new service allows patients to start by completing an intake questionnaire that covers their health history, current medications, and goals for treatment. A U.S.-licensed clinician then reviews this information to decide on a case-by-case basis whether a prescription is appropriate. While Ozempic is FDA-approved for treating type 2 diabetes, it can also be prescribed for weight management, a use that remains off-label and at the discretion of the clinician.

Patients who qualify for a prescription will receive ongoing care coaching to support their treatment plan. This coaching is designed to provide a steady point of contact throughout the process, rather than a one-time appointment followed by silence.

Meant Health's expansion of telehealth access to GLP-1 medications is part of its mission to offer personalized GLP-1 weight-care support through its telehealth platform. The company brings together an online clinical assessment, licensed oversight through OpenLoop Health, ongoing care coaching, and supplemental wellness resources. It does not diagnose or prescribe; that responsibility is handled by its clinical partners.

The platform aims to make GLP-1 medications more accessible to patients who might not otherwise have easy access to them. By providing a straightforward way to connect with licensed clinicians, Meant Health hopes to help more individuals manage their health conditions and achieve their weight management goals.

For those interested in learning more about the evaluation process and what to expect, Meant Health provides detailed information on its website. The company's expansion of telehealth services to include FDA-approved GLP-1 medications is a significant step in its ongoing efforts to support patients through personalized care and coaching.